Monte Rosa Therapeutics, Inc. Payments to Acquire Marketable Securities
Monte Rosa Therapeutics, Inc. (GLUE) reported Payments to Acquire Marketable Securities of $408.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $76.07M, a 299.70% increase year-over-year.
- Monte Rosa Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $332.00M, a 140.55% increase year-over-year.
- Monte Rosa Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $153.66M, a 126.10% increase year-over-year.
- Monte Rosa Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $65.97M, a 103.78% increase year-over-year.
- Monte Rosa Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $376.68M, a 63.52% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $230.36M, a 123.32% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $103.15M, a 73.17% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $384.42M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $76.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $408.07M 10-Q · filed 2026-08-06 | $561.73M derived: sum of 3 quarters · filed 2026-08-06 | $627.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $332.00M 10-Q · filed 2026-05-07 | $485.66M derived: sum of 2 quarters · filed 2026-05-07 | $551.63M derived: sum of 3 quarters · filed 2026-05-07 | $570.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $153.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $219.63M derived: sum of 2 quarters · filed 2026-03-17 | $238.66M derived: sum of 3 quarters · filed 2026-08-06 | $376.68M 10-K · filed 2026-03-17 |
| 2025-09-30 | $65.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $85.00M derived: sum of 2 quarters · filed 2026-08-06 | $223.02M 10-Q · filed 2025-11-06 | $290.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $19.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $157.05M 10-Q · filed 2026-08-06 | $225.01M derived: sum of 3 quarters · filed 2026-08-06 | $257.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $138.01M 10-Q · filed 2026-05-07 | $205.97M derived: sum of 2 quarters · filed 2026-05-07 | $238.35M derived: sum of 3 quarters · filed 2026-05-07 | $312.31M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $67.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $100.33M derived: sum of 2 quarters · filed 2026-03-17 | $174.29M derived: sum of 3 quarters · filed 2026-03-17 | $230.36M 10-K · filed 2026-03-17 |
| 2024-09-30 | $32.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $106.33M derived: sum of 2 quarters · filed 2025-11-06 | $162.40M 10-Q · filed 2025-11-06 | $189.91M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $73.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $130.03M 10-Q · filed 2025-08-07 | $157.54M derived: sum of 3 quarters · filed 2025-08-07 | $165.35M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $56.07M 10-Q · filed 2025-05-08 | $83.58M derived: sum of 2 quarters · filed 2025-05-08 | $91.39M derived: sum of 3 quarters · filed 2025-05-08 | $91.39M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $27.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $35.33M derived: sum of 2 quarters · filed 2025-03-20 | $35.33M derived: sum of 3 quarters · filed 2025-03-20 | $103.15M 10-K · filed 2025-03-20 |
| 2023-09-30 | $7.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $7.81M derived: sum of 2 quarters · filed 2024-11-07 | $75.64M 10-Q · filed 2024-11-07 | $170.00M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $67.82M 10-Q · filed 2024-08-08 | $162.19M derived: sum of 3 quarters · filed 2024-08-08 | $221.59M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $67.82M 10-Q · filed 2024-05-09 | $162.19M derived: sum of 2 quarters · filed 2024-05-09 | $221.59M derived: sum of 3 quarters · filed 2024-05-09 | $273.28M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $94.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $153.76M derived: sum of 2 quarters · filed 2024-03-14 | $205.46M derived: sum of 3 quarters · filed 2024-03-14 | $384.42M 10-K · filed 2024-03-14 |
| 2022-09-30 | $59.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $111.09M derived: sum of 2 quarters · filed 2023-11-09 | $290.05M 10-Q · filed 2023-11-09 | $290.05M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $51.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $230.65M 10-Q · filed 2023-08-10 | $230.65M derived: sum of 3 quarters · filed 2023-08-10 | |
| 2022-03-31 | $178.96M 10-Q · filed 2023-05-11 | $178.96M derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 10-K · filed 2023-03-16 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |